Randomized Trialvery high evidence
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
JAMA·January 2, 2024·PMID 38078870
Why it mattersThis trial provides direct evidence that tirzepatide’s weight loss benefits are not durable after discontinuation, reinforcing the concept of obesity as a chronic condition requiring ongoing pharmacotherapy. It informs long-term treatment strategies and patient counseling about the need for sustained therapy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled